Millennium Management’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Millennium Management’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-124,229	Closed	-$826K	–	4753
2019 Q2	$826K	Buy	124,229 +85,181	+218%	+$324K	﹤0.01%	2917
2019 Q1	$139K	Sell	39,048 -80,989	-67%	-$440K	﹤0.01%	3805
2018 Q4	$476K	Sell	120,037 -30,830	-20%	-$394K	﹤0.01%	3001
2018 Q3	$2.98M	Sell	150,867 -81,505	-35%	-$2.06M	﹤0.01%	2145
2018 Q2	$7.38M	Buy	232,372 +143,029	+160%	+$5.15M	0.01%	1524
2018 Q1	$3.31M	Buy	89,343 +33,560	+60%	+$2.21M	﹤0.01%	2037
2017 Q4	$4.41M	Buy	+55,783	New	+$4.13M	0.01%	1801

Other funds holding MLNT

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Millennium Management's MLNT Position: Q3 2019 in Review

Millennium Management sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q3 2019, closing a stake of 124,229 shares — an estimated $826K sold.

Millennium Management first reported a position in MLNT in Q4 2017 and held it in 7 quarters. The position peaked at $7.38M in Q2 2018. 47 funds tracked by Wall St. Rank hold MLNT as of Q3 2019.

Millennium Management reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
Millennium Management sold 124,229 Melinta Therapeutics, Inc. Common Stock shares in Q3 2019, an estimated $826K.
Millennium Management first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 7 quarters.
Millennium Management's Melinta Therapeutics, Inc. Common Stock position peaked at $7.38M in Q2 2018.
47 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q3 2019.

Based on Millennium Management's 13F filing for Q3 2019, filed 14 Nov 2019.